Astrocyte-like cells derived from human oral mucosa stem cells provide neuroprotection in vitro and in vivo

Stem Cells Translational Medicine

Volumn 3, Issue 3, 2014, Pages 375-386

  Ganz, Javier ^a   Arie, Ina ^a   Ben Zur, Tali ^a   Dadon Nachum, Michal ^a   Pour, Sammy ^b   Araidy, Shareef ^b   Pitaru, Sandu ^a   Offen, Daniel ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b BARUCH PADEH MEDICAL CENTER   (Israel)

Author keywords

Astrocytes; Cell therapy; Neural differentiation; Oral mucosa stem cells

Indexed keywords

ALPHA BUNGAROTOXIN; BRAIN DERIVED NEUROTROPHIC FACTOR; EXCITATORY AMINO ACID TRANSPORTER 1; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; PROTEIN S100B; SOMATOMEDIN C; SYNAPTOPHYSIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL DIFFERENTIATION; CELL MIGRATION; CELL SURVIVAL; CELL VIABILITY; ENGRAFTMENT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN ORAL MUCOSA STEM CELL; HYPOXIA; IMMUNOCHEMISTRY; IMMUNOFLUORESCENCE TEST; MALE; MOTONEURON; MOTOR PERFORMANCE; MOUTH MUCOSA; NEUROMUSCULAR SYNAPSE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; RAT; REAL TIME POLYMERASE CHAIN REACTION; SCIATIC NERVE INJURY; STEM CELL; STEM CELL TRANSPLANTATION; UPREGULATION; WESTERN BLOTTING;

ASTROCYTES; CELL THERAPY; NEURAL DIFFERENTIATION; ORAL MUCOSA STEM CELLS;

ANIMALS; ASTROCYTES; BIOLOGICAL MARKERS; BRAIN-DERIVED NEUROTROPHIC FACTOR; BUNGAROTOXINS; CELL DIFFERENTIATION; CULTURE MEDIA, CONDITIONED; GENE EXPRESSION; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MOTOR NEURONS; MOUTH MUCOSA; NEUROMUSCULAR JUNCTION; PERIPHERAL NERVE INJURIES; RATS; RATS, SPRAGUE-DAWLEY; S100 CALCIUM BINDING PROTEIN BETA SUBUNIT; SCIATIC NERVE; STEM CELLS; SYNAPTOPHYSIN;

EID: 84896275587     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2013-0074     Document Type: Article

References (66)

1. Ganz J, Lev N, Melamed E et al. Cell replacement therapy for Parkinson's disease: How close are we to the clinic? Expert Rev Neurother 2011;11:1325-1339.
2. Kimelberg HK, NedergaardM. Functions of astrocytes and their potential as therapeutic targets. Neurotherapeutics 2010;7:338-353.
3. Yamanaka K, Boillee S, Roberts EA et al. Mutant SOD1 in cell types other than motor neurons and oligodendrocytes accelerates onset of disease in ALS mice. Proc Natl Acad Sci USA 2008;105:7594-7599.
4. Barbeito LH, Pehar M, Cassina P et al. A role for astrocytes in motor neuron loss in amyotrophic lateral sclerosis. Brain Res Brain Res Rev 2004;47:263-274.
5. Miquel E, Cassina A, Martínez-Palma L et al. Modulation of astrocytic mitochondrial function by dichloroacetate improves survival and motor performance in inherited amyotrophic lateral sclerosis. PLoS One 2012;7:e34776.
6. Díaz-Amarilla P, Olivera-Bravo S, Trias E et al. Phenotypically aberrant astrocytes that promote motoneuron damage in a model of inherited amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2011;108:18126-18131.
7. Nakajima K, Hida H, Shimano Y et al. GDNF is a major component of trophic activity in DAdepleted striatum for survival and neurite extension of DAergic neurons. Brain Res 2001; 916:76-84.
8. Berglöf E, Af Bjerkén S, Strömberg I. Glial influence on nerve fiber formation from rat ventral mesencephalic organotypic tissue cultures. J Comp Neurol 2007;501:431-442.
9. L' Episcopo F, Tirolo C, Testa N et al. Glia as a turning point in the therapeutic strategy of Parkinson's disease. CNS Neurol Disord Drug Targets 2010;9:349-372.
10. Faulkner JR, Herrmann JE, Woo MJ et al. Reactive astrocytes protect tissue and preserve function after spinal cord injury. J Neurosci 2004;24:2143-2155.
11. Franklin RJ, Blakemore WF. Glial-cell transplantation and plasticity in the O-2A lineage-implications for CNS repair. Trends Neurosci 1995;18:151-156.
12. Lepore AC, Rauck B, Dejea C et al. Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nat Neurosci 2008;11:1294-1301.
13. Sofroniew MV, Vinters HV. Astrocytes: Biology and pathology. Acta Neuropathol 2010; 119:7-35.
14. Gritti A, Bonfanti L. Neuronal-glial interactions in central nervous system neurogenesis: The neural stem cell perspective. Neuron Glia Biol 2007;3:309-323.
15. Sadan O, Bahat-Stromza M, Barhum Y et al. Protective effects of neurotrophic factorsecreting cells in a 6-OHDArat model of Parkinson disease. Stem Cells Dev 2009;18:1179-1190.
16. Sadan O, Melamed E, Offen D. Bonemarrow-derived mesenchymal stem cell therapy for neurodegenerative diseases. Expert Opin Biol Ther 2009;9:1487-1497.
17. Sadan O, Shemesh N, Cohen Y et al. Adult neurotrophic factor-secreting stem cells: A potential novel therapy for neurodegenerative diseases. Isr Med Assoc J 2009;11:201-204.
18. Bahat-Stroomza M, Barhum Y, Levy YS et al. Induction of adult human bone marrow mesenchymal stromal cells into functional astrocyte-like cells: Potential for restorative treatment in Parkinson's disease. J Mol Neurosci 2009;39:199-210.
19. Dadon-Nachum M, Sadan O, Srugo I et al. Differentiated mesenchymal stem cells for sciatic nerve injury. Stem Cell Rev 2011;7: 664-671.
20. Xiong N, Zhang Z, Huang J et al. VEGFexpressing human umbilical cord mesenchymal stem cells, an improved therapy strategy for Parkinson's disease. Gene Ther 2011;18: 394-402.
21. Kitiyanant N, Kitiyanant Y, Svendsen CN et al. BDNF-, IGF-1-and GDNF-secreting human neural progenitor cells rescue amyloid b-induced toxicity in cultured rat septal neurons. Neurochem Res 2012;37:143-152.
22. Ozdinler PH, Macklis JD. IGF-I specifically enhances axon outgrowth of corticospinal motor neurons. Nat Neurosci 2006;9:1371-1381.
23. Dobrowolny G, Giacinti C, Pelosi L et al. Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J Cell Biol 2005;168:193-199.
24. Azzouz M, Ralph GS, Storkebaum E et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004;429:413-417.
25. Zheng C, Sköld MK, Li J et al. VEGF reduces astrogliosis and preserves neuromuscular junctions in ALS transgenic mice. Biochem Biophys Res Commun 2007;363:989-993.
26. Acsadi G, Anguelov RA, Yang H et al. Increased survival and function of SOD1 mice after glial cell-derived neurotrophic factor gene therapy. HumGene Ther 2002;13:1047-1059.
27. Mohajeri MH, Figlewicz DA, Bohn MC. Intramuscular grafts of myoblasts genetically modified to secrete glial cell line-derived neurotrophic factor prevent motoneuron loss and disease progression in a mouse model of familial amyotrophic lateral sclerosis. Hum Gene Ther 1999;10:1853-1866.
28. Barhum Y, Gai-Castro S, Bahat-Stromza Met al. Intracerebroventricular transplantation of human mesenchymal stem cells induced to secrete neurotrophic factors attenuates clinical symptoms in a mouse model of multiple sclerosis. J Mol Neurosci 2010;41:129-137.
29. Fisher-Shoval Y, Barhum Y, Sadan O et al. Transplantation of placenta-derived mesenchymal stem cells in the EAE mouse model of MS. J Mol Neurosci 2012;48:176-184.
30. Sadan O, Shemesh N, Barzilay R et al. Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: A potential therapy for Huntington's disease. Exp Neurol 2012;234:417-427.
31. Levkovitch-Verbin H, Sadan O, Vander S et al. Intravitreal injections of neurotrophic factors secreting mesenchymal stem cells are neuroprotective in rat eyes following optic nerve transection. Invest Ophthalmol Vis Sci 2010; 51:6394-6400.
32. Marynka-Kalmani K, Treves S, Yafee M et al. The lamina propria of adult human oral mucosa harbors a novel stem cell population. STEM CELLS 2010;28:984-995.
33. Le Douarin N, Dulac C, Dupin E et al. Glial cell lineages in the neural crest. Glia 1991;4: 175-184.
34. Le Douarin NM, Creuzet S, Couly G et al. Neural crest cell plasticity and its limits. Development 2004;131:4637-4650.
35. Dupin E, Real C, Glavieux-Pardanaud C et al. Reversal of developmental restrictions in neural crest lineages: Transition from Schwann cells to glial-melanocytic precursors in vitro. Proc Natl Acad Sci USA 2003;100: 5229-5233.
36. Davies LC, LockeM, WebbRDet al. Amultipotent neural crest-derived progenitor cell population is resident within the oral mucosa lamina propria. Stem Cells Dev 2010;19:819-830.
37. Durham HD, Dahrouge S, Cashman NR. Evaluation of the spinal cord neuron X neuroblastoma hybrid cell line NSC-34 as a model for neurotoxicity testing. Neurotoxicology 1993; 14:387-395.
38. Mousavi K, Jasmin BJ. BDNF is expressed in skeletal muscle satellite cells and inhibits myogenic differentiation. J Neurosci 2006;26: 5739-5749.
39. Clow C, Jasmin BJ. Brain-derived neurotrophic factor regulates satellite cell differentiation and skeletal muscle regeneration. Mol Biol Cell 2010;21:2182-2190.
40. Lu B, Malcuit C, Wang S et al. Long-term safety and function of RPE from human embryonic stem cells in preclinical models of macular degeneration. STEM CELLS 2009;27: 2126-2135.
41. Schwartz SD, Hubschman JP, Heilwell G et al. Embryonic stem cell trials for macular degeneration: A preliminary report. Lancet 2012; 379:713-720.
42. Pitaru S, Savion N, Hekmati H et al. Molecular and cellular interactions of a cementum attachment protein with periodontal cells and cementum matrix components. J Periodontal Res 1993;28:560-562.
43. Suzuki M, McHugh J, Tork C et al. Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. Mol Ther 2008;16:2002-2010.
44. DezawaM. Systematic neuronal andmuscle induction systems in bone marrow stromal cells: The potential for tissue reconstruction in neurodegenerative and muscle degenerative diseases. Med Mol Morphol 2008;41:14-19.
45. Shimizu S, Kitada M, Ishikawa H et al. Peripheral nerve regeneration by the in vitro differentiated-human bone marrow stromal cells with Schwann cell property. Biochem Biophys Res Commun 2007;359:915-920.
46. Mohajeri M, Farazmand A, Mohyeddin BonabMet al. FOXP3 gene expression in multiple sclerosis patients pre-and post mesenchymal stem cell therapy. Iran J Allergy Asthma Immunol 2011;10:155-161.
47. Dadon-Nachum MB-ZT. Srugo I, ShamirH M, Melamed E, Yaffe D, Offen D. Therapeutic effect of myogenic cells modified to express neurotrophic factors in a rat model of sciatic nerve injury. Journal of Stem Cells and Regenerative Medicine 2012;8:22-26.
48. Jin Y, Neuhuber B, Singh A et al. Transplantation of human glial restricted progenitors and derived astrocytes into a contusion model of spinal cord injury. J Neurotrauma 2011;28: 579-594.
49. Lepore AC, O'Donnell J, Kim AS et al. Human glial-restricted progenitor transplantation into cervical spinal cord of the SOD1 mouse model of ALS. PLoS One 2011;6:e25968.
50. Dadon-Nachum M, Melamed E, Offen D. Stem cells treatment for sciatic nerve injury. Expert Opin Biol Ther 2011;11:1591-1597.
51. Stenderup K, Justesen J, Clausen C et al. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone 2003;33:919-926.
52. Zhou S, Greenberger JS, Epperly MW et al. Age-related intrinsic changes in human bone-marrow-derived mesenchymal stem cells and their differentiation to osteoblasts. Aging Cell 2008;7:335-343.
53. Stolzing A, Jones E, McGonagle D et al. Age-related changes in human bone marrowderived mesenchymal stem cells: Consequences for cell therapies. Mech Ageing Dev 2008; 129:163-173.
54. Dupin E, Glavieux C, Vaigot P et al. Endothelin 3. induces the reversion of melanocytes to glia through a neural crest-derived glialmelanocytic progenitor. Proc Natl Acad Sci USA 2000;97:7882-7887.
55. Pinkas-Kramarski R, Eilam R, Spiegler O et al. Brain neurons and glial cells express Neu differentiation factor/heregulin: A survival factor for astrocytes. Proc Natl Acad Sci USA 1994; 91:9387-9391.
56. Kerber G, Streif R, Schwaiger FW et al. Neuregulin-1 isoforms are differentially expressed in the intact and regenerating adult rat nervous system. J Mol Neurosci 2003;21:149-165.
57. Adachi T, Takanaga H, KunimotoMet al. Influence of LIF and BMP-2 on differentiation and development of glial cells in primary cultures of embryonic rat cerebral hemisphere. J Neurosci Res 2005;79:608-615.
58. Kang K, Song MR. Diverse FGF receptor signaling controls astrocyte specification and proliferation. Biochem Biophys Res Commun 2010;395:324-329.
59. Qian X, Davis AA, Goderie SK et al. FGF2 concentration regulates the generation of neurons and glia from multipotent cortical stem cells. Neuron 1997;18:81-93.
60. Song MR, Ghosh A. FGF2-induced chromatin remodeling regulates CNTF-mediated gene expression and astrocyte differentiation. Nat Neurosci 2004;7:229-235.
61. Ravin R, Hoeppner DJ, Munno DM et al. Potency and fate specification in CNS stem cell populations in vitro. Cell Stem Cell 2008;3: 670-680.
62. Raballo R, Rhee J, Lyn-Cook R et al. Basic fibroblast growth factor (Fgf2) is necessary for cell proliferation and neurogenesis in the developing cerebral cortex. J Neurosci 2000;20: 5012-5023.
63. Vaccarino FM, Schwartz ML, Raballo R et al. Changes in cerebral cortex size are governed by fibroblast growth factor during embryogenesis. Nat Neurosci 1999;2:848.
64. Stanimirovic DB, Ball R, Small DL et al. Developmental regulation of glutamate transporters and glutamine synthetase activity in astrocyte cultures differentiated in vitro. Int J Dev Neurosci 1999;17:173-184.
65. Bayatti N, Engele J. Cyclic AMP differentially regulates the expression of fibroblast growth factor and epidermal growth factor receptors in cultured cortical astroglia. Neuroscience 2002;114:81-89.
66. Condorelli DF, Dell'Albani P, Mudo G et al. Expression of neurotrophins and their receptors in primary astroglial cultures: Induction by cyclic AMP-elevating agents. J Neurochem 1994;63:509-516.